Sab biotherapeutics announces clinical partnership with naval medical research center to advance potential influenza treatment

Sioux falls, s.d., march 25, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that the navy medical research command (nmrc) is moving forward with a safety and tolerability study to evaluate sab-176, a therapy being investigated for use as a pre- and post-exposure prophylactic treatment for influenza type a and type b, pursuant to the cooperative research and development agreement that governs the relationship between sab and the nmrc.
SABS Ratings Summary
SABS Quant Ranking